SW-1115-C3

N/A

Report date: 2026/05/13 11:17:38

Base Information

Drug NameSW-1115-C3

Drug Alias NamemRNA-based personalised cancer vaccines (Stemirna Therapeutics)Neoantigen antigen mRNA tumour vaccine (Stemirna Therapeutics)Personalised mRNA tumour vaccine (Stemirna Therapeutics)SW-1115-C3SW 1115C3 +[7]

ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccine > personalized mRNA cancer vaccinesVaccines > Application > Therapeutic vaccine

Mechanisms of ActionGene transferenceImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungEsophageal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustraliaAustriaMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPreclinical

Originator CompaniesStemirna Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesStemirna Therapeutics

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungEsophageal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A